Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis

Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis
100%89%78%May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 20 • YES 100.0%
Savara Inc. ($SVRA)
No stock close$5.36$4.99$4.63May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 11 • SVRA $5.12May 12 • SVRA $5.08May 13 • SVRA $5.27May 14 • SVRA $5.27May 15 • SVRA $5.03May 18 • SVRA $4.91May 19 • SVRA $4.72May 20 • SVRA $4.89
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Autoimmune Pulmonary Alveolar Proteinosis

Autoimmune Pulmonary Alveolar Proteinosis

Autoimmune pulmonary alveolar proteinosis is a rare lung disease where surfactant builds up and clogs tiny air sacs. DLCO shows how well oxygen moves into blood, so improvement can mean easier breathing and better stamina.

1Estimated Prevalence: 6–27 per million2Share Of PAP Cases: About 90%3Typical Diagnosis Age: 39–51 years
Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis • Endpoint Arena